An Efficacy and Safety Study of Erdafitinib (JNJ-42756493) in Participants With Urothelial Cancer
Janssen Research & Development, LLC
Janssen Research & Development, LLC
National Cancer Institute (NCI)
University of California, San Francisco
Centre Oscar Lambret
University of Chicago
Medical University of South Carolina
Wake Forest University Health Sciences
Dana-Farber Cancer Institute
Cairo University
Northwestern University
M.D. Anderson Cancer Center
University of Cincinnati
Weill Medical College of Cornell University
Weill Medical College of Cornell University
Thomas Jefferson University
Hopital Foch
M.D. Anderson Cancer Center
St. Jude Children's Research Hospital
NRG Oncology
Northwestern University
University of Arizona
Al-Mustansiriyah University
University of Michigan Rogel Cancer Center
Mayo Clinic
MedSIR
University of Milano Bicocca
Amsterdam UMC, location VUmc
McGill University Health Centre/Research Institute of the McGill University Health Centre
Dana-Farber Cancer Institute
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Fudan University
Kaohsiung Medical University Chung-Ho Memorial Hospital
University of Pittsburgh
Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS
Ente Ospedaliero Ospedali Galliera
Oslo University Hospital
Peking Union Medical College Hospital
UNC Lineberger Comprehensive Cancer Center
Rigshospitalet, Denmark
Karolinska Institutet
Wake Forest University Health Sciences
Emory University
Queensland Centre for Gynaecological Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Hospital Municipal São José
Semnan University of Medical Sciences
Fundació Sant Joan de Déu
AHS Cancer Control Alberta
Zhongnan Hospital
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)